Lipids & metabolic liver disease
Correlation between atherogenic index of plasma and cardiovascular disease risk across Cardiovascular–kidney–metabolic syndrome stages 0–3: a nationwide prospective cohort study
Authors' conclusion
Herein, AIP levels correlated significantly positively with CVD risk in individuals in CKM stages 0-3, with metabolic syndrome as a key mediating factor. These findings suggest that AIP levels could be valuable not only for CVD risk assessment but also for clinical screening.
Study context
- Population
- Adults aged ≥45 years in Cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3, China Health and Retirement Longitudinal Study (CHARLS), 2011–2012 baseline (Wave 1); Atherogenic Index of Plasma (AIP) = ln(TG/High-Density Lipoprotein Cholesterol (HDL-C))
- Participants
- 7,708 adults
- Exposure
- Highest vs lowest AIP levels; per unit increase in AIP
- Outcome
- CVD incidence, based on self-reported past diagnoses
Methodological detailsnationwide, Cox proportional risk model, subgroup and mediation analyses
- Nationwide
- Cox proportional risk model
- Subgroup and mediation analyses
Main finding
As reported in the abstract
CVD incidence
Estimate (95% CI)
Highest AIPvs Lowest AIP
HR 1.22(1.08–1.39)
Per unit increase in AIP
risk ratio 1.31(1.11–1.55)
Observational data: associations, not effects.
Further findings
Mediation by metabolic syndrome of the AIP–CVD association
- Proportion of association mediated by metabolic syndrome
- 12.3% (p = 0.024)
Original publication
Correlation between atherogenic index of plasma and cardiovascular disease risk across Cardiovascular–kidney–metabolic syndrome stages 0–3: a nationwide prospective cohort study. Cardiovasc Diabetol. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →